The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study
Open accessAbstract
BACKGROUND: Glucocorticoids are the cornerstone treatment of polymyalgia rheumatica (PMR) but induce adverse events. OBJECTIVES: To evaluate the efficacy and safety of first-line tocilizumab in PMR. METHODS: In a prospective open-label study (ClinicalTrials.gov: NCT01713842), 20 glucocorticoid-free patients fulfilling Chuang's PMR criteria, with symptom onset within the last 12 months and a PMR activity score (PMR-AS) >10, each received three tocilizumab infusions at 4-week intervals, without glucocorticoids, followed by oral prednisone from weeks 12 to 24 (0.15 mg/kg if PMR-AS ≤10 and 0.30 mg/kg otherwise). The primary end point was the proportion of patients with PMR-AS≤10 at week 12. RESULTS: Baseline median PMR-AS was 36.6 (IQR 30.4-43.8). At week 12, all patients had PMR-AS≤10 and received the low prednisone dosage. Median PMR-AS at weeks 12 and 24 was 4.5 (3.2-6.8) and 0.95 (IQR 0.4-2), respectively (p<0.001 vs baseline for both time points). No patient required rescue treatment. Positron emission tomography-CT showed significant improvements. The most common adverse events were transient neutropenia (n=3) and leucopenia (n=5); in one patient, the second tocilizumab infusion was omitted due to leucopenia. CONCLUSIONS: Tocilizumab monotherapy is effective in recent-onset PMR. Randomised controlled trials are warranted. TRIAL REGISTRATION NUMBER: NCT01713842.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TCZ is also effective and safe for PMR treatment.114,115”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasgupta, B., Cimmino, M. A., Kremers, H. M., Schmidt, W., Schirmer, M., Salvarani, C., Bachta, A., Dejaco, C., Duftner, C., Jensen, H. S., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200329 · Cited by 676
Chuang, T., HUNDER, G. G., ILSTRUP, D. M., & KURLAND, L. T. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-5-672 · Cited by 527
HUSKISSON, E. C., & HART, F. D. (1987) · Elsevier eBooks · doi:10.1016/b978-0-7236-0571-3.50187-7 · Cited by 436
Dejaco, C., Singh, Y. P., Perel, P., Hutchings, A., Camellino, D., Mackie, S. L., Abril, A., Bachta, A., Balint, P. V., Barraclough, K., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207492 · Cited by 334
Dejaco, C., Singh, Y. P., Perel, P., Hutchings, A., Camellino, D., Mackie, S. L., Abril, A., Bachta, A., Balint, P. V., Barraclough, K., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39333 · Cited by 312
Prednisone plus Methotrexate for Polymyalgia Rheumatica
Caporali, R. F., Cimmino, M. A., Ferraccioli, G., Gerli, R., Klersy, C., Salvarani, C., Montecucco, C., & for the Systemic Vasculitis Study Group of the Italian Society for Rheumatology (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-7-200410050-00005 · Cited by 260
BSR and BHPR guidelines for the management of polymyalgia rheumatica
Dasgupta, B., Borg, F., Hassan, N., Barraclough, K., Bourke, B., Fulcher, J., Hollywood, J., Hutchings, A., Kyle, V., Nott, J., et al. (2009) · Rheumatology · doi:10.1093/rheumatology/kep303a · Cited by 249
A disease activity score for polymyalgia rheumatica
Leeb, B. F., & Bird, H. A. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011379 · Cited by 193
Carmona, F. D., Mackie, S. L., Martín, J., Taylor, J., Vaglio, A., Eyre, S., Bossini‐Castillo, L., Castañeda, S., Cid, M. C., Hernández‐Rodríguez, J., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.02.009 · Cited by 180
Dejaco, C., Singh, Y. P., Perel, P., Hutchings, A., Camellino, D., Mackie, S. L., Matteson, E. L., & Dasgupta, B. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207578 · Cited by 102
Cited by
Sorted by citations
Translating IL-6 biology into effective treatments
Choy, E., Benedetti, F. D., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 680
Interleukin (IL-6) ImmunotherapyPreprint
Tanaka, T., Narazaki, M., & Kishimoto, T. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028456 · Cited by 419
González-Gay, M. Á., Matteson, E. L., & Castañeda, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31825-1 · Cited by 264
Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities
Dejaco, C., Brouwer, E., Mason, J. C., Buttgereit, F., Matteson, E. L., & Dasgupta, B. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.142 · Cited by 225
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Metadata
- Authors
- Devauchelle-Pensec, V., Berthelot, J. M., Cornec, D., Renaudineau, Y., Marhadour, T., Jousse-Joulin, S., Querellou, S., Garrigues, F., De Bandt, M., Gouillou, M., & Saraux, A.
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Bretagne Occidentale (FR)
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 75
- Issue
- 8
- Pages
- 1506-1510
- ISSN
- 0003-4967 (ISSN-L)
- PMC
- PMC4975852
- OpenAlex
- W2290444582
- Cited by
- 171
- References
- 22
- Citations by year
- 2026: 15 · 2025: 10 · 2024: 18 · 2023: 19 · 2022: 19 · 2021: 17 · 2020: 19 · 2019: 11 · 2018: 18 · 2017: 16 · 2016: 8
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Annals of the Rheumatic Diseases (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Otitis Media and Relapsing Polychondritis
- Keywords
- tocilizumab, polymyalgia rheumatica, steroid-sparing therapy, prednisone, IL-6 inhibition, neutropenia, leukopenia, treatment efficacy and safety
- MeSH terms
- Positron Emission Tomography Computed Tomography, Aged, Drug Administration Schedule, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Infusions, Intravenous, Longitudinal Studies, Male, Middle Aged, Polymyalgia Rheumatica, Prednisone, Prospective Studies, Severity of Illness Index, Treatment Outcome, Antirheumatic Agents, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
